A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions
Cystic Fibrosis
Interventions
DRUG

ELX/TEZ/IVA

Fixed-dose combination tablets for oral administration.

DRUG

IVA

Tablets for oral administration.

Trial Locations (24)

Unknown

The Prince Charles Hospital, Chermside

Alfred Hospital, Melbourne

Institute for Respiratory Health, Nedlands

Telethon Kids Institute, Nedlands

The Royal Children's Hospital, Parkville

Mater Adult Hospital, South Brisbane

Queensland Children's Hospital, South Brisbane

Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels

Universitair Ziekenhuis Brussel - Campus Jette, Brussels

Universitair Ziekenhuis Gent, Ghent

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven

University of Calgary Medical Clinic of the Foothills Medical Centre, Calgary

Stollery Children's Hospital, Edmonton

Queen Elizabeth II Health Sciences Center, Halifax

Klinika Nemoci Plicnich a Tuberkulozy, Brno

Fakultni nemocnice v Motole, Prague

Hospital Saint Joan de Deu, Barcelona

Hospital Universitari Vall d Hebron, Barcelona

Hospital Universitari Vall d´Hebron Servicio de Broncoscopia, Barcelona

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Ramon y Cajal, Madrid

Hospital Virgen de la Arrixaca, Murcia

Corporacio Sanitaria Parc Tauli - Sabadell Hospital Universitari, Sabadell

Hospital Universitario Virgen del Rocio, Seville

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY